Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 2/20 | 0.45 |
| ▸ | CDK8 | P49336 | 2/20 | 0.45 |
| ▸ | PIM1 | P11309 | 1/20 | 0.45 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | PLAU | P00749 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28507167 | 0.87 | ALDH1A1 (0.55) | CCNCCDK8PIM1PIM2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL17205026 | 0.85 | ALDH1A1 (0.54) | CCNCCDK8PIM1PIM2ALDH1A1 | |
| SCHEMBL21070701 | 0.81 | NLRP3 (0.41) | ALDH1A1PDE4BHDAC1HDAC8HDAC6 | |
| SCHEMBL31734475 | 0.77 | HPGDS (0.50) | ALDH1A1PDE4BGRM2HDAC1HDAC8 | |
| SCHEMBL17406967 | 0.75 | PAICS (0.39) | ALDH1A1PDE4BHDAC1HDAC8HDAC6 | |
| SCHEMBL18386991 | 0.74 | IRAK4 (0.48) | ALDH1A1PDE4BHDAC1HDAC8HDAC6 | |
| SCHEMBL16896617 | 0.73 | KDM5B (0.42) | PIM1PIM2ALDH1A1PDE4BHDAC1 | |
| SCHEMBL27229256 | 0.73 | PTPN1 (0.36) | ALDH1A1PDE4BHDAC1HDAC8HDAC6 | |
| SCHEMBL3436258 | 0.72 | ALDH1A1 (0.47) | ALDH1A1PDE4BHDAC1HDAC8HDAC6 | |
| SCHEMBL24335121 | 0.72 | ALOX5AP (0.38) | CCNCCDK8DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4613773-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-3731869-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20250000985-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-01-02 | — | — | US | disclosed |
| US-12168057-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-12-17 | — | — | US | disclosed |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-11723980-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| US-11723980-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| US-20230106066-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-06 | — | — | US | disclosed |
| US-20220089592-A1 | IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS | BIOGEN MA INC. | 2022-03-24 | — | — | US | disclosed |
| EP-3911652-A1 | IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS | Biogen MA Inc. (US) | 2021-11-24 | — | — | EP | disclosed |
| US-10874743-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-10874743-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| CN-112105385-A | IRAK degrading agents and uses thereof | 凯麦拉医疗公司 | 2020-12-18 | — | — | CN | disclosed |
| EP-3731869-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2020-11-04 | — | — | EP | disclosed |
| WO-2020150626-A1 | IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS | BIOGEN MA INC. (US) | 2020-07-23 | — | — | WO | disclosed |
| WO-2020150626-A1 | IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS | BIOGEN MA INC. (US) | 2020-07-23 | — | — | WO | disclosed |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10874743-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | CCNC 3820/4885CDK8 646/4885PIM1 274/4885 |
| US-20230106066-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CCNC 3820/4885CDK8 646/4885PIM1 274/4885 |
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CCNC 3820/4885CDK8 646/4885PIM1 274/4885 |
| US-20250000985-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CCNC 3820/4885CDK8 646/4885PIM1 274/4885 |
| US-11723980-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | CCNC 3820/4885CDK8 646/4885PIM1 274/4885 |
| US-12168057-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | CCNC 3820/4885CDK8 646/4885PIM1 274/4885 |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CCNC 3820/4885CDK8 646/4885PIM1 274/4885 |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CCNC 3820/4885CDK8 646/4885PIM1 274/4885 |
| US-20220089592-A1 | IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS | IRAK4, IRAK2, IRAK1 | CCNC 3263/4885CDK8 492/4885PIM1 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.